The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

March 31, 2017

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Icaritin

Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg

Trial Locations (3)

Cancer institute & hospital, chinese academy of medical sciences, Beijing

Beijing Shenogen Biomedical Co., Ltd, Beijing

NanJing PLA 81 Hospital, Nanjing

All Listed Sponsors

collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

NanJing PLA 81 Hospital

OTHER

collaborator

307 Hospital of PLA

OTHER

collaborator

Qingdao University

OTHER

lead

Beijing Shenogen Biomedical Co., Ltd

INDUSTRY

NCT01972672 - The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter